Journal
CANCERS
Volume 13, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/cancers13040750
Keywords
bleomycin; polyphosphate; pulmonary fibrosis; prevention of fibrosis; COVID-19; anti-SARS-CoV-2 activity
Categories
Funding
- ERC Advanced Investigator Grant [268476]
- ERC-PoC grants [324564, 662486, 767234]
- European Commission [604036, 311848]
- International Human Frontier Science Program
- BiomaTiCS research initiative of the University Medical Center, Mainz
- BMBF [13GW0403B]
- BMWi [ZF4294002AP9]
Ask authors/readers for more resources
Bleomycin (BLM) is a medication used to treat cancer, but its side effects, such as pulmonary fibrosis, can be reduced by co-administration with inorganic polyphosphate (polyP), potentially through upregulating the gene for BLM hydrolase. This study may also have implications for using BLM in COVID-19 patients, as polyP prevents the binding of SARS-CoV-2 to host cells.
Simple Summary: Bleomycin (BLM) is a medication introduced used to treat various types of cancer, including testicular cancer, ovarian cancer, and Hodgkin's disease. Its most serious side effect is pulmonary fibrosis and impaired lung function. Using A549 human lung cells it is shown that, in parallel to an increased cell toxicity and DNA damage, BLM causes a marked enlargement of the cell nucleus. This effect is abolished by inorganic polyphosphate (polyP), if this physiological polymer is administered together with BLM. The detoxification of BLM is-most likely-caused by the upregulation of the gene encoding the BLM hydrolase which inactivates BLM in vitro and in vivo. This study contributes also to a rational application in COVID-19 patients since polyP prevents binding of SARS-CoV-2 to host cells. Abstract: The anti-cancer antitumor antibiotic bleomycin(s) (BLM) induces athyminic sites in DNA after its activation, a process that results in strand splitting. Here, using A549 human lung cells or BEAS-2B cells lunc cells, we show that the cell toxicity of BLM can be suppressed by addition of inorganic polyphosphate (polyP), a physiological polymer that accumulates and is released from platelets. BLM at a concentration of 20 mu g ml(-1) causes a decrease in cell viability (by similar to 70%), accompanied by an increased DNA damage and chromatin expansion (by amazingly 6-fold). Importantly, the BLM-caused effects on cell growth and DNA integrity are substantially suppressed by polyP. In parallel, the enlargement of the nuclei/chromatin in BLM-treated cells (diameter, 20-25 mu m) is normalized to similar to 12 mu m after co-incubation of the cells with BLM and polyP. A sequential application of the drugs (BLM for 3 days, followed by an exposure to polyP) does not cause this normalization. During co-incubation of BLM with polyP the gene for the BLM hydrolase is upregulated. It is concluded that by upregulating this enzyme polyP prevents the toxic side effects of BLM. These data might also contribute to an application of BLM in COVID-19 patients, since polyP inhibits binding of SARS-CoV-2 to cellular ACE2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available